Abstract
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have